MDPI and ACS Style
Rossi, V.; Berchialla, P.; Giannarelli, D.; Nisticò, C.; Ferretti, G.; Gasparro, S.; Russillo, M.; Catania, G.; Vigna, L.; Mancusi, R.L.;
et al. Should All Patients With HR-Positive HER2-Negative Metastatic Breast Cancer Receive CDK 4/6 Inhibitor As First-Line Based Therapy? A Network Meta-Analysis of Data from the PALOMA 2, MONALEESA 2, MONALEESA 7, MONARCH 3, FALCON, SWOG and FACT Trials. Cancers 2019, 11, 1661.
https://doi.org/10.3390/cancers11111661
AMA Style
Rossi V, Berchialla P, Giannarelli D, Nisticò C, Ferretti G, Gasparro S, Russillo M, Catania G, Vigna L, Mancusi RL,
et al. Should All Patients With HR-Positive HER2-Negative Metastatic Breast Cancer Receive CDK 4/6 Inhibitor As First-Line Based Therapy? A Network Meta-Analysis of Data from the PALOMA 2, MONALEESA 2, MONALEESA 7, MONARCH 3, FALCON, SWOG and FACT Trials. Cancers. 2019; 11(11):1661.
https://doi.org/10.3390/cancers11111661
Chicago/Turabian Style
Rossi, Valentina, Paola Berchialla, Diana Giannarelli, Cecilia Nisticò, Gianluigi Ferretti, Simona Gasparro, Michelangelo Russillo, Giovanna Catania, Leonardo Vigna, Rossella Letizia Mancusi,
and et al. 2019. "Should All Patients With HR-Positive HER2-Negative Metastatic Breast Cancer Receive CDK 4/6 Inhibitor As First-Line Based Therapy? A Network Meta-Analysis of Data from the PALOMA 2, MONALEESA 2, MONALEESA 7, MONARCH 3, FALCON, SWOG and FACT Trials" Cancers 11, no. 11: 1661.
https://doi.org/10.3390/cancers11111661